New hope for tough blood cancers? experimental drug enters human testing
NCT ID NCT03922100
Summary
This study tested a new drug called NMS-03592088 in adults whose acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML) had returned or did not respond to standard treatments. The main goals were to find a safe dose and see if the drug could help control the cancer. The trial was terminated early and involved 63 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Grande Ospedale Metropolitano Niguarda
Milan, MI, 20162, Italy
-
ASST Papa Giovanni XXIII
Bergamo, BG, 24127, Italy
-
ASST Spedali Civili di Brescia
Brescia, 25123, Italy
-
Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
Bologna, 40138, Italy
-
CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque
Pessac, 33604, France
-
Centre Hospitalier Lyon-Sud
Pierre-Bénite, 69495, France
-
Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu
Nantes, 44000, France
-
Centre Hospitalier du Mans
Le Mans, 72037, France
-
Fondazione Policlinico Universitario Agostino Gemelli
Roma, 00168, Italy
-
Hospital Universitari i Politècnic La Fe
Valencia, 46026, Spain
-
Istituto Clinico Humanitas
Rozzano, MI, 20089, Italy
Conditions
Explore the condition pages connected to this study.